Patent restoration and the cost of pharmaceuticals .: YN5-156/2018E-PDF
"This report estimates additional drug costs to Canadian consumers from changes to the Patent Law as negotiated under the Canada-European Union Comprehensive Economic and Trade Agreement (CETA). A two-year certificate of supplementary protection (CSP; elsewhere termed patent restoration, and used synonymously here since CSP provides patent-like protection) will delay the introduction of generic alternatives, and likely keep prices higher than they otherwise would be. The report also estimates the fiscal cost to the federal government of compensating provinces for increased costs to provincial public drug programs”--Verso of cover.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.856574&sl=0
| Department/Agency | Canada. Office of the Parliamentary Budget Officer. |
|---|---|
| Title | Patent restoration and the cost of pharmaceuticals . |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Format | Electronic |
| Electronic document | |
| Note(s) | Issued also in French under title: La prolongation de la durée des brevets et le coût des médicaments. Cover title. "26 April 2018." Includes bibliographical references. |
| Publishing information | Ottawa : Office of the Parliamentary Budget Officer, 2018. |
| Description | 41 p. : col. charts |
| Catalogue number |
|
| Subject terms | Drugs Prices Patent extensions Government policy |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.- Date modified: